Algernon CEO Discusses Ifenprodil Sale to Seyltx and DMT as a Treatment for Stroke and TBI

Mar 18, 2025

How Algernon Pharmaceuticals is Unlocking Sub-Psychedelic DMT for Stroke and TBI Treatment

Mar 18, 2025

Disseminated on Behalf of: Algernon Pharmaceuticals Algernon sold its Ifenprodil research program in Q2 of this year to U.S. based Seyltx, Inc. for US$2 million and a 20% common share equity position Sub-psychedelic DMT has been shown to promote brain healing...

The Dales Report – Why Psychedelic Treatments Will Benefit Investors and Healthcare

Feb 27, 2023

Is Drug Repurposing the new breakthrough for faster approval of Psychedelic-assisted treatments? In this TDR Psychedelic Exclusive, we speak with the CEO of Algernon Pharmaceuticals (CNSX: AGN) (OTC: AGNPF) Christopher Moreau who explains the company’s recent...

Radius Research Interview – Algernon NeuroScience Initiates TBI Research Program with DMT

Feb 22, 2023

CEO Christopher J. Moreau provides an update on Algernon Pharmaceuticals Inc. announcement that its subsidiary Algernon NeuroScience (AGN Neuro) has added a new clinical research program for the treatment of Traumatic Brain Injury (TBI) with AP-188...

Proactive Investors CEO Interview – Algernon NeuroScience completes first dosing in Phase 1 clinical study of DMT

Feb 16, 2023

Algernon Pharmaceuticals CEO Christopher J. Moreau joined Steve Darling from Proactive to share news the Company’s subsidiary Algernon NeuroScience has announced it has completed the first dosing in its Phase 1 clinical study of an intravenous formulation of AP-188 or...

SR Times – “Drug Could Possibly Both Reduce Acute Damage of the Stroke” – How DMT Could be the Future of Stroke Treatment

Feb 7, 2023

  “Drug Could Possibly Both Reduce Acute Damage of the Stroke” – How DMT Could be the Future of Stroke Treatment     Dr Rick Strassman, one of the most well-known researchers and authors on DMT, shares with SR Times his expert knowledge on using...